Vinay Kumar
Vinay Kumar has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Gauri Goyal
KIET Group of Institutions (KIET) Delhi‐NCR Ghaziabad Uttar Pradesh India
4 shared publications - Mohamad Taleuzzaman
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Maulana Azad University, Village Bujhawar, Tehsil Luni, Jodhpur 342008, Rajashthan, India
4 shared publications - Ajay Kumar Pal
Department of Pharmacology Delhi Pharmaceutical Sciences and Research University (DPSRU) New Delhi India
2 shared publications B. K. Singh
Department of Pharmacology, KIET School of Pharmacy, Ghaziabad, India
2 shared publications- Hitesh Kumar Dewangan
University Institute of Pharma Sciences (UIPS), Chandigarh University, NH-95 Chandigarh Ludhiana Highway, Mohali, Punjab, India
2 shared publications Kandasamy Nagarajan
KIET Group of Institutions (KIET) Delhi‐NCR Ghaziabad Uttar Pradesh India
2 shared publications
Latest Publications
- 22 June 2026
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (2) , 172
Tofacitinib attenuates imiquimod-induced psoriasis via JAK-STAT inhibition: in vivo and in silico study
Dysregulated Janus kinase–signal transducer and activator of transcription (JAK-STAT) signalling is a hallmark of psoriasis, a long-term, immune-mediated inflammatory skin condition. The preclinical pharmacological profile and structural binding mechanism of tofacitinib, a pan-JAK inhibitor, in the Imiquimod (IMQ)-induced mouse model are still not well understood, despite its therapeutic effectiveness in psoriasis. Using molecular docking and 200 ns molecular dynamics (MD) simulation, assess tofacitinib’s in vivo anti-psoriatic effectiveness in the IMQ-induced BALB/c mouse model and describe its binding interactions with the JAK2 kinase domain (PDB: 3FUP). Topical IMQ (62.5 mg/day) was administered to BALB/c mice for seven days. Dexamethasone (1 mg/kg, p.o.) and tofacitinib (1, 3, 10 mg/kg, p.o., b.i.d.) were given at the same time. Psoriasis Area and Severity Index (PASI) scores, body weight, ear thickness, cytokine levels (IL-1β, IL-6, IL-17 A, and IL-10; RT-PCR and ELISA), and histopathological characteristics were evaluated. Glide XP (Schrödinger) was used for molecular docking, while Desmond (Schrödinger) was used for MD simulation utilising the OPLS4 force field over 200 ns. Tofacitinib (3 and 10 mg/kg) was equally effective as dexamethasone in reducing ear thickness, PASI scores, and pro-inflammatory cytokines (IL-1β, IL-6, and IL-17 A) while also improving histopathological markers and restoring IL-10 levels. Molecular docking demonstrated that tofacitinib has a higher binding affinity than dexamethasone (− 6.043 kcal/mol; − 51.81 kcal/mol), with crucial hydrogen bonds to LEU932 and GLU930 in the JAK2 hinge region (GlideScore: − 10.292 kcal/mol; ΔG: − 96.20 kcal/mol). Over 200 ns, MD modelling verified steady complex formation (RMSD: 1.95 Å; RMSF: 1.13 Å; Rg: 3.71 Å; SASA: 44.27 Å2). By inhibiting the JAK-STAT system, tofacitinib has notable anti-psoriatic activity in the IMQ model, and in silico investigations corroborate its strong structural binding stability. These results provide credence to JAK inhibition as a mechanistically sound psoriasis treatment approach. Graphical abstract The alternative text for this image may have been generated using AI.
- 22 June 2026
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (2) , 172
Tofacitinib attenuates imiquimod-induced psoriasis via JAK-STAT inhibition: in vivo and in silico study
Dysregulated Janus kinase–signal transducer and activator of transcription (JAK-STAT) signalling is a hallmark of psoriasis, a long-term, immune-mediated inflammatory skin condition. The preclinical pharmacological profile and structural binding mechanism of tofacitinib, a pan-JAK inhibitor, in the Imiquimod (IMQ)-induced mouse model are still not well understood, despite its therapeutic effectiveness in psoriasis. Using molecular docking and 200 ns molecular dynamics (MD) simulation, assess tofacitinib’s in vivo anti-psoriatic effectiveness in the IMQ-induced BALB/c mouse model and describe its binding interactions with the JAK2 kinase domain (PDB: 3FUP). Topical IMQ (62.5 mg/day) was administered to BALB/c mice for seven days. Dexamethasone (1 mg/kg, p.o.) and tofacitinib (1, 3, 10 mg/kg, p.o., b.i.d.) were given at the same time. Psoriasis Area and Severity Index (PASI) scores, body weight, ear thickness, cytokine levels (IL-1β, IL-6, IL-17 A, and IL-10; RT-PCR and ELISA), and histopathological characteristics were evaluated. Glide XP (Schrödinger) was used for molecular docking, while Desmond (Schrödinger) was used for MD simulation utilising the OPLS4 force field over 200 ns. Tofacitinib (3 and 10 mg/kg) was equally effective as dexamethasone in reducing ear thickness, PASI scores, and pro-inflammatory cytokines (IL-1β, IL-6, and IL-17 A) while also improving histopathological markers and restoring IL-10 levels. Molecular docking demonstrated that tofacitinib has a higher binding affinity than dexamethasone (− 6.043 kcal/mol; − 51.81 kcal/mol), with crucial hydrogen bonds to LEU932 and GLU930 in the JAK2 hinge region (GlideScore: − 10.292 kcal/mol; ΔG: − 96.20 kcal/mol). Over 200 ns, MD modelling verified steady complex formation (RMSD: 1.95 Å; RMSF: 1.13 Å; Rg: 3.71 Å; SASA: 44.27 Å2). By inhibiting the JAK-STAT system, tofacitinib has notable anti-psoriatic activity in the IMQ model, and in silico investigations corroborate its strong structural binding stability. These results provide credence to JAK inhibition as a mechanistically sound psoriasis treatment approach. Graphical abstract The alternative text for this image may have been generated using AI.
- Open Access
- 5 May 2026
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 45 (6) , 295-303
Therapeutic role of lactoferrin against doxorubicin-induced cardiotoxicity in Wistar rats
- 5 May 2026
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 45 (6) , 295-303
Open AccessTherapeutic role of lactoferrin against doxorubicin-induced cardiotoxicity in Wistar rats
- 3 February 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (2) , e03014
Enhanced Anti‐Psoriasis Efficacy of Curcumin via Optimized Nanostructured Lipid Carrier‐Embedded Nanogel System
Psoriasis is a chronic inflammatory skin disorder in which existing topical and systemic therapies are often limited by adverse effects and poor patient compliance. This study aimed to develop a curcumin‐loaded solid lipid nanoparticle CUR‐SLN (curcumin solid lipid nanoparticles) loaded nanogel to enhance topical delivery and therapeutic efficacy. CUR‐SLNs were prepared using a solvent diffusion method and characterized for particle size, polydispersity index (PDI), zeta potential, entrapment efficiency, and morphology. The optimized nanoparticles (133.90 ± 2.45 nm; PDI 0.325 ± 0.21; entrapment efficiency 89.50% ± 4.52%) were incorporated into a Carbopol‐based gel to formulate the CUR‐SLN nanogel. The nanogel was evaluated for appearance, viscosity, pH, and texture profile, along with in vitro drug release, ex vivo skin permeation, drug retention, and stability. Compared with a conventional curcumin gel, the CUR‐SLN‐loaded nanogel demonstrated sustained drug release over 48 h and significantly enhanced skin permeation and retention. In vivo studies in a psoriasis‐induced mouse model showed a marked reduction in Psoriasis Area and Severity Index scores and significant downregulation of key pro‐inflammatory cytokines (interferon‐α [IFN‐α], IL‐23, interleukin‐17 [IL‐17], tumor necrosis factor‐α [TNF‐α]) ( p < 0.001). Histological evaluation further confirmed restoration of normal skin structure in treated animals. Overall, the CUR‐SLN‐loaded nanogel represents a promising and safer topical therapeutic strategy for psoriasis, supporting its potential for further clinical development.
- 3 February 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (2) , e03014
Enhanced Anti‐Psoriasis Efficacy of Curcumin via Optimized Nanostructured Lipid Carrier‐Embedded Nanogel System
Psoriasis is a chronic inflammatory skin disorder in which existing topical and systemic therapies are often limited by adverse effects and poor patient compliance. This study aimed to develop a curcumin‐loaded solid lipid nanoparticle CUR‐SLN (curcumin solid lipid nanoparticles) loaded nanogel to enhance topical delivery and therapeutic efficacy. CUR‐SLNs were prepared using a solvent diffusion method and characterized for particle size, polydispersity index (PDI), zeta potential, entrapment efficiency, and morphology. The optimized nanoparticles (133.90 ± 2.45 nm; PDI 0.325 ± 0.21; entrapment efficiency 89.50% ± 4.52%) were incorporated into a Carbopol‐based gel to formulate the CUR‐SLN nanogel. The nanogel was evaluated for appearance, viscosity, pH, and texture profile, along with in vitro drug release, ex vivo skin permeation, drug retention, and stability. Compared with a conventional curcumin gel, the CUR‐SLN‐loaded nanogel demonstrated sustained drug release over 48 h and significantly enhanced skin permeation and retention. In vivo studies in a psoriasis‐induced mouse model showed a marked reduction in Psoriasis Area and Severity Index scores and significant downregulation of key pro‐inflammatory cytokines (interferon‐α [IFN‐α], IL‐23, interleukin‐17 [IL‐17], tumor necrosis factor‐α [TNF‐α]) ( p < 0.001). Histological evaluation further confirmed restoration of normal skin structure in treated animals. Overall, the CUR‐SLN‐loaded nanogel represents a promising and safer topical therapeutic strategy for psoriasis, supporting its potential for further clinical development.
- 3 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 52
AI-Powered Predictive Modeling to Optimize Pharmaceutical Formulation and Precise Drug Delivery in Modified Release Tablets
- 3 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 52
AI-Powered Predictive Modeling to Optimize Pharmaceutical Formulation and Precise Drug Delivery in Modified Release Tablets
- 11 November 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (1) , e02217
In Silico, In Vitro, and In Vivo Evaluation of Woodfordia Fruticosa for Cardio Protection against Doxorubicin‐Induced Cardiomyopathy
This study aimed to evaluate the therapeutic potential of Woodfordia fruticosa , known for its cardioprotective properties, using in silico, in vitro, and in vivo methods. Fourier‐transform infrared spectroscopy (FTIR) and gas chromatography–mass spectrometry (GC–MS) analyses were used to identify and characterize the bioactive compounds in W. fruticosa . Molecular docking with dock score assessed the binding affinities of hecogenin, β‐sitosterol, and pulmatin. Antioxidant potential was evaluated using 2,2‐diphenyl‐1‐picrylhydrazyl (DPPH) and ferric reducing antioxidant power (FRAP) assays. In vivo experiments involved inducing cardiomyopathy in Wistar albino rats with doxorubicin (16 mg/kg, ip) and treating them with W. fruticosa flower extract at doses of 100, 200, and 400 mg/kg for 16 days. Molecular docking studies revealed that hecogenin, β‐sitosterol, and pulmatin exhibited strong binding affinities against human protein kinase ZAK, with Dock scores of −12.07, −11.42, and −11.04, respectively, surpassing the standard drug ramipril (−9.32). FTIR and GC–MS confirmed the presence of key phytoconstituents, including β‐sitosterol, hecogenin, ellagic acid, kaempferol, and 2‐hydroxy‐1,4‐naphthoquinone (Lawsone). In vitro antioxidant assays demonstrated significant free radical scavenging activity comparable to ascorbic acid. In vivo studies in Wistar albino rats showed that W. fruticosa flower extract significantly ( p < 0.001) improved electrocardiogram (ECG) parameters, and significantly ( p < 0.001) reduced cardiac biomarkers, including creatine kinase myocardial band (CK‐MB), lactate dehydrogenase (LDH), and cardiac troponin I, and mitigated histopathological damage in a dose‐dependent manner caused by doxorubicin. The 400 mg/kg dose exhibited the most pronounced cardioprotective effects, normalizing ECG patterns, decreasing myocardial injury, and reducing fibrosis. W. fruticosa flower extract exhibited significant cardioprotective potential via the human protein kinase ZAK pathway against doxorubicin‐induced cardiomyopathy through in silico, in vitro, and in vivo evaluations. These findings suggest W. fruticosa as a promising natural agent for cardiomyopathy management, warranting further studies to elucidate its mechanisms, optimize dosing, and validate long‐term safety and efficacy.
- 11 November 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (1) , e02217
In Silico, In Vitro, and In Vivo Evaluation of Woodfordia Fruticosa for Cardio Protection against Doxorubicin‐Induced Cardiomyopathy
This study aimed to evaluate the therapeutic potential of Woodfordia fruticosa , known for its cardioprotective properties, using in silico, in vitro, and in vivo methods. Fourier‐transform infrared spectroscopy (FTIR) and gas chromatography–mass spectrometry (GC–MS) analyses were used to identify and characterize the bioactive compounds in W. fruticosa . Molecular docking with dock score assessed the binding affinities of hecogenin, β‐sitosterol, and pulmatin. Antioxidant potential was evaluated using 2,2‐diphenyl‐1‐picrylhydrazyl (DPPH) and ferric reducing antioxidant power (FRAP) assays. In vivo experiments involved inducing cardiomyopathy in Wistar albino rats with doxorubicin (16 mg/kg, ip) and treating them with W. fruticosa flower extract at doses of 100, 200, and 400 mg/kg for 16 days. Molecular docking studies revealed that hecogenin, β‐sitosterol, and pulmatin exhibited strong binding affinities against human protein kinase ZAK, with Dock scores of −12.07, −11.42, and −11.04, respectively, surpassing the standard drug ramipril (−9.32). FTIR and GC–MS confirmed the presence of key phytoconstituents, including β‐sitosterol, hecogenin, ellagic acid, kaempferol, and 2‐hydroxy‐1,4‐naphthoquinone (Lawsone). In vitro antioxidant assays demonstrated significant free radical scavenging activity comparable to ascorbic acid. In vivo studies in Wistar albino rats showed that W. fruticosa flower extract significantly ( p < 0.001) improved electrocardiogram (ECG) parameters, and significantly ( p < 0.001) reduced cardiac biomarkers, including creatine kinase myocardial band (CK‐MB), lactate dehydrogenase (LDH), and cardiac troponin I, and mitigated histopathological damage in a dose‐dependent manner caused by doxorubicin. The 400 mg/kg dose exhibited the most pronounced cardioprotective effects, normalizing ECG patterns, decreasing myocardial injury, and reducing fibrosis. W. fruticosa flower extract exhibited significant cardioprotective potential via the human protein kinase ZAK pathway against doxorubicin‐induced cardiomyopathy through in silico, in vitro, and in vivo evaluations. These findings suggest W. fruticosa as a promising natural agent for cardiomyopathy management, warranting further studies to elucidate its mechanisms, optimize dosing, and validate long‐term safety and efficacy.
- 12 April 2025
- Published by Wiley in Chemistry & Biodiversity
- p. e202403103
In‐silico Screening of Kewra Oil Composition and Validation of Its Anti‐arthritic Efficacy Against Experimental Rat Model
Rheumatoid Arthritis, a prevalent chronic inflammatory condition, imposes significant burdens on affected individuals globally. Kewra oil derived from Pandanus odoratissimus flowers, is reputed for its anti‐inflammatory properties in traditional medicine. This study aimed to assess the pharmacological effects of P. odoratissimus in an experimental rat model of arthritis along with an in‐silico study. An in‐silico study performed with PDB ID: 3GN8 and Dexamethasone was taken as standard reference. Thirty‐six male Wistar rats were randomized into six groups: normal control, arthritis control, standard (Dexamethasone‐ 1 mg/kg, s.c.), and three treatment groups receiving varied doses of extract P. odoratissimus (50, 100, and 200 mg/kg, oral). Arthritis was induced by injecting Freund's complete adjuvant into the rats' right hind paws. Treatment groups received oral P. odoratissimus extract once daily for 4 weeks. Paw volume, joint circumference, arthritis index, hematological parameters, inflammatory markers, and histopathological changes were assessed to check the arthritis severity. In Kewra oil, 56 bioactive were identified by gas chromatography‐mass spectrometry, and out of them, 54 molecules have dock score and dG binding value, which have more and less anti‐inflammatory effects. Out of 54 molecules, 30 molecules have good hydrogen bond interaction with different types of amino acids in receptors. The in‐vivo results state that rats when treated with P. odoratissimus, showed significant (p < 0.05) arthritis index, joint circumference, paw volume, improved weight‐bearing capacity, and inflammatory markers of rats treated with P. odoratissimus were significantly less than those in arthritis‐control rats (p < 0.05). The predicted anti‐inflammatory effects of the Kewra oil were validated by performing an in‐vivo study. P. odoratissimus holds potential as a natural remedy for arthritis, meriting continued exploration for therapeutic application.
- 12 April 2025
- Published by Wiley in Chemistry & Biodiversity
- p. e202403103
In‐silico Screening of Kewra Oil Composition and Validation of Its Anti‐arthritic Efficacy Against Experimental Rat Model
Rheumatoid Arthritis, a prevalent chronic inflammatory condition, imposes significant burdens on affected individuals globally. Kewra oil derived from Pandanus odoratissimus flowers, is reputed for its anti‐inflammatory properties in traditional medicine. This study aimed to assess the pharmacological effects of P. odoratissimus in an experimental rat model of arthritis along with an in‐silico study. An in‐silico study performed with PDB ID: 3GN8 and Dexamethasone was taken as standard reference. Thirty‐six male Wistar rats were randomized into six groups: normal control, arthritis control, standard (Dexamethasone‐ 1 mg/kg, s.c.), and three treatment groups receiving varied doses of extract P. odoratissimus (50, 100, and 200 mg/kg, oral). Arthritis was induced by injecting Freund's complete adjuvant into the rats' right hind paws. Treatment groups received oral P. odoratissimus extract once daily for 4 weeks. Paw volume, joint circumference, arthritis index, hematological parameters, inflammatory markers, and histopathological changes were assessed to check the arthritis severity. In Kewra oil, 56 bioactive were identified by gas chromatography‐mass spectrometry, and out of them, 54 molecules have dock score and dG binding value, which have more and less anti‐inflammatory effects. Out of 54 molecules, 30 molecules have good hydrogen bond interaction with different types of amino acids in receptors. The in‐vivo results state that rats when treated with P. odoratissimus, showed significant (p < 0.05) arthritis index, joint circumference, paw volume, improved weight‐bearing capacity, and inflammatory markers of rats treated with P. odoratissimus were significantly less than those in arthritis‐control rats (p < 0.05). The predicted anti‐inflammatory effects of the Kewra oil were validated by performing an in‐vivo study. P. odoratissimus holds potential as a natural remedy for arthritis, meriting continued exploration for therapeutic application.
- Open Access
- 30 April 2024
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 40 (2) , 506-513
An Experimental Study on the Evaluation of Boerhavia Diffusa in the Treatment of Psoriasis in Albino Mice
Psoriasis, impacting 2-3% of the population, poses a chronic challenge. Conventional treatments having limited effectiveness and adverse effects; recent immunological insights foster targeted therapies, while herbal medications gain attention for safety and accessibility. The current research aimed to assess the efficacy of Boerhavia diffusa in mitigating psoriasis induced by imiquimod in mice. Study induced psoriasis in albino mice using 5% imiquimod cream for 5 days, then treated with Boerhavia diffusa (1% and 3%) and Tazarotene (0.1%). Parameters were assessed in the study viz. PASI score, spleen weight/body weight ratio, serum inflammatory markers (IL-17, IL-23, and TNF-α), and skin histopathology. Mice treated with imiquimod exhibited noteworthy elevations in PASI score, spleen weight/body weight ratio, and serum inflammatory markers, which were effectively suppressed by Boerhavia diffusa and Tazarotene applications. Topically application of Boerhavia diffusa significantly ameliorated psoriasis, suggesting it as a promising, well-tolerated alternative to enhance the quality of life for affected individuals.
- 30 April 2024
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 40 (2) , 506-513
Open AccessAn Experimental Study on the Evaluation of Boerhavia Diffusa in the Treatment of Psoriasis in Albino Mice
Psoriasis, impacting 2-3% of the population, poses a chronic challenge. Conventional treatments having limited effectiveness and adverse effects; recent immunological insights foster targeted therapies, while herbal medications gain attention for safety and accessibility. The current research aimed to assess the efficacy of Boerhavia diffusa in mitigating psoriasis induced by imiquimod in mice. Study induced psoriasis in albino mice using 5% imiquimod cream for 5 days, then treated with Boerhavia diffusa (1% and 3%) and Tazarotene (0.1%). Parameters were assessed in the study viz. PASI score, spleen weight/body weight ratio, serum inflammatory markers (IL-17, IL-23, and TNF-α), and skin histopathology. Mice treated with imiquimod exhibited noteworthy elevations in PASI score, spleen weight/body weight ratio, and serum inflammatory markers, which were effectively suppressed by Boerhavia diffusa and Tazarotene applications. Topically application of Boerhavia diffusa significantly ameliorated psoriasis, suggesting it as a promising, well-tolerated alternative to enhance the quality of life for affected individuals.
- Open Access
- 30 April 2024
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 40 (2) , 569-579
Herbal Remedies in Wound Healing: A Comprehensive Review of Plants and Non-Clinical Applications
The phenomenon of wound healing encompasses a coordinated sequence of cellular and biochemical phases collaborating synergistically to promote the restoration of the injured tissue. Tissue repair is complex, posing challenges in wound management. Healing involves three phases: inflammatory, proliferative, and remodeling. Treatments include antibiotics, antiseptics, and extracts, but synthetic drugs have limitations. There is growing interest in plant-based formulations for effective wound treatment. Medicinal plants are increasingly recognized for their wound healing potential with lower side effects, particularly in diabetic, infected, or open wounds, supported by studies highlighting various identified mechanisms for improved healing. Medicinal plants such as Allium sativum, Boerhavia diffusa, Calendula officinalis, Crocus sativus, Curcuma longa L., Glycyrrhiza glabra L., Melaleuca alternifolia, Woodfordia fruticosa, etc. have demonstrated wound healing properties and have proven effective in treating wounds. This review highlights medicinal plants in wound healing, emphasizing in-vivo models, specifically examining their effectiveness in excision and incision wound healing.
- 30 April 2024
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 40 (2) , 569-579
Open AccessHerbal Remedies in Wound Healing: A Comprehensive Review of Plants and Non-Clinical Applications
The phenomenon of wound healing encompasses a coordinated sequence of cellular and biochemical phases collaborating synergistically to promote the restoration of the injured tissue. Tissue repair is complex, posing challenges in wound management. Healing involves three phases: inflammatory, proliferative, and remodeling. Treatments include antibiotics, antiseptics, and extracts, but synthetic drugs have limitations. There is growing interest in plant-based formulations for effective wound treatment. Medicinal plants are increasingly recognized for their wound healing potential with lower side effects, particularly in diabetic, infected, or open wounds, supported by studies highlighting various identified mechanisms for improved healing. Medicinal plants such as Allium sativum, Boerhavia diffusa, Calendula officinalis, Crocus sativus, Curcuma longa L., Glycyrrhiza glabra L., Melaleuca alternifolia, Woodfordia fruticosa, etc. have demonstrated wound healing properties and have proven effective in treating wounds. This review highlights medicinal plants in wound healing, emphasizing in-vivo models, specifically examining their effectiveness in excision and incision wound healing.
- 22 December 2022
- Published by Springer Nature in 3 Biotech
- Vol. 13 (1) , 1-18
Comparative evaluation of natural neuroprotectives and their combinations on chronic immobilization stress-induced depression in experimental mice
The present study evaluates the potential of neuroprotective phytochemicals-rutin (R), resveratrol (Res), 17β-estradiol (17β-E2), and their different combinations against chronic immobilization stress (CIS)-induced depression-like behaviour in male albino mice. Here, the mice were exposed to stress via immobilization of their four limbs under a restrainer for 6 h daily until 7 days of the induction after 30 min of respective drug treatment in different mice groups. The result found the protective effect of these phytoconstituents and their combinations against CIS-induced depression due to their ability to suppress oxidative stress, restore mitochondria, HPA-axis modulation, neurotransmitter level, stress hormones, and inflammatory markers. Also, the combination drug regimens of these phytoconstituents showed synergistic results in managing the physiological and biochemical features of depression. Thus, these neuroprotective could be utilized well in combination to manage depression-like symptoms during episodic stress. Furthermore, such results could be well justified when administered in polyherbal formulation with these neuroprotective as major components. In addition, an advanced study can be designed at the molecular and epigenetics level using a formulation based on these neuroprotective.
- 22 December 2022
- Published by Springer Nature in 3 Biotech
- Vol. 13 (1) , 1-18
Comparative evaluation of natural neuroprotectives and their combinations on chronic immobilization stress-induced depression in experimental mice
The present study evaluates the potential of neuroprotective phytochemicals-rutin (R), resveratrol (Res), 17β-estradiol (17β-E2), and their different combinations against chronic immobilization stress (CIS)-induced depression-like behaviour in male albino mice. Here, the mice were exposed to stress via immobilization of their four limbs under a restrainer for 6 h daily until 7 days of the induction after 30 min of respective drug treatment in different mice groups. The result found the protective effect of these phytoconstituents and their combinations against CIS-induced depression due to their ability to suppress oxidative stress, restore mitochondria, HPA-axis modulation, neurotransmitter level, stress hormones, and inflammatory markers. Also, the combination drug regimens of these phytoconstituents showed synergistic results in managing the physiological and biochemical features of depression. Thus, these neuroprotective could be utilized well in combination to manage depression-like symptoms during episodic stress. Furthermore, such results could be well justified when administered in polyherbal formulation with these neuroprotective as major components. In addition, an advanced study can be designed at the molecular and epigenetics level using a formulation based on these neuroprotective.